

### INTERNATIONAL COOPERATION OPPORTUNITIES: HORIZON EUROPE 2021-2027

Hicham Abghay (Steinbeis 2i GmbH)

20.11.2020



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825904.

# **Project Identity: SENET**

Funding: EU Research & Innovation Programme Horizon 2020

### Runtime: 01/2019 - 06/2021

Consortium: Five in Europe & Four partners from China





# **SENET Major Objectives**



### **Overall objectives**

SENET aims to

- **increase collaborative efforts** addressing common health research and innovation challenges.
- create a sustainable health networking and knowledge hub, which facilitates favourable conditions for a dialogue between Chinese and EU research and innovation entities.

### Specific objectives

SENET aims to

- identify health challenges of common interest between the EU and China
- develop a sustainable health networking hub between the EU and China
- implement collaborative health research initiatives between the EU and China





# **SENET Main Activities**

### <u>Create a collaboration environment with mutual interest to tackle</u> <u>common health challenges</u>

- Panorama of Health Research Priorities in China & Europe: "Scoping paper: Review on health research and innovation priorities EU & China"
- Catalogue of Health Research and Innovation Initiatives and Actors:
   *"Map of major funding agencies and stakeholders in EU & China"*
- "Guide for health researchers from Europe and China through the funding landscape"

See our public reports under: <u>https://www.senet-hub.eu/public-report/</u>

- Series of Stakeholder Engagement Workshops:  $\rightarrow$  <u>Call for experts OPEN!</u>
- Define future health priorities with us <u>HERE</u>!!





# Recommendations for EU-China health research and innovation cooperation

- Overview of the health priorities in the EU and China
  - Reinforcing the prevention and control of major and infectious diseases;
  - Strengthening the management of environmental problems affecting health;
  - Promoting the development of sustainable healthcare systems;
  - Cooperating on standardisation and research ethics;
  - Improving the health funding mechanisms in China.







# **SENET Partnering Opportunities**

### Increase transnational collaboration and capacity building

Power Partnering events:

- <u>Global Alliance for Chronic Diseases Prevention and/or early diagnosis of cancer</u>
- Towards the new generation of clinical trials trials methodology research
- <u>New approaches for clinical management and prevention of resistant bacterial</u> infections in high prevalence settings
- Advancing the safety assessment of chemicals without the use of animal testing
- <u>AI for Genomics and Personalised Medicine</u>





# **SENET Virtual Hackathons**



### Increase transnational collaboration and capacity building

*Virtual Ideation Hackathons (2020-2021):* 

- Al for Health Imaging in cancer research
- Al applications for health management notably chronic diseases
- Simulation technologies and animal free testing for rare diseases/precision medicine
- Biological scaffolds for tissue regeneration and repair
- Environmental effects on health and wellbeing
- Novel technologies for <u>next generation vaccines</u>













# **Horizon Europe**

is the Commission proposal for an **initial € 100 billion** research and innovation funding programme for seven years (2021-2027)




to strengthen the EU's scientific and technological bases

to boost Europe's innovation capacity, competitiveness



and jobs

to deliver on citizens' priorities and sustain our socio-economic model and values





# Credits: https://www.un.org/sustainabledevelopment/sustainable-development-goals/

# Horizon Europe: investing in R&I to shape our future

- The vision:
  - " a Europe that protects, a Europe that empowers, a Europe that defends" Jean-Claude Juncker
- Tackling climate change
- Helping to achieve Sustainable
   Development Goals & Green Deal
- Boosting the Union's competitiveness sustainability and resilience








### Horizon Europe: evolution not revolution


### Specific objectives of the Programme

SENET – Webseries 2020 C





# Budget: ~ €85,5 billion\*



\* Council proposition as of 29.09.2020





### **Horizon Europe: Framework Layers**

Multi-Annual Strategic planing (Valid ~ 7 years) Outlined structure, research modalities, measures & instruments

Strategic planing Process (SPP) (valid ~4 Years) Outlined Strategy and consultations with MS, MEP and *stakeholders* 

Work Programm

(Valid ~1-2 years)

20 Nov. 2020

Setting into context, rational, scope, single topics & budgets





# **Achieved steps so far: One Billion Question!**






### **Horizon Europe: evolution not revolution**

### Specific objectives of the Programme

SENET – Webseries 2020 C





### **R&I Expected Impacts and Intervention Areas**

1.Staying healthy in a rapidly changing society ()1.2.2. Environmental and Social Health Determinantsfor Health Research (ERA4HEALTH Determinants2. Living and working in a health- promoting environment ()1.2.2. Environmental and Social Health DeterminantsPartnership on Risk Assessme Chemicals3. Tackling diseases and reducing disease burden ()1.2.3. Non-Communicable and Rare DiseasesEU-Africa Global Health partne (EDCTP)4. Ensuring access to innovative, sustainable and high-quality health care ()1.2.6. Health Care SystemsNare Diseases Diseases5. Unlocking the full potential of new tools, technologies and digital1.2.5. Tools, Technologies and Digital Solutions for Health and Care, includingPersonalised Medicine	Expected Impacts (destinations)	Intervention areas covered	European Partnerships (co- programmed and co-funded)
changing society ()1.2.2. Environmental and Social Health DeterminantsInternet Research (Environmental and Social Health Determinants2. Living and working in a health- promoting environment ()1.2.2. Environmental and Social Health 		1.2.1. Health throughout the Life Course	Fostering a European Research Area
2. Living and working in a health- promoting environment ()DeterminantsChemicals3. Tackling diseases and reducing disease burden ()1.2.1. Health throughout the Life CourseEU-Africa Global Health partne (EDCTP)3. Tackling diseases and reducing disease burden ()1.2.4. Infectious Diseases, including poverty-related and neglected diseasesRare Diseases4. Ensuring access to innovative, sustainable and high-quality health care ()1.2.6. Health Care SystemsTransformation of Health Care Sy EIT KIC Health5. Unlocking the full potential of new tools, technologies and digital1.2.5. Tools, Technologies and Digital Solutions for Health and Care, includingPersonalised Medicine			for Health Research (ERA4HEALTH)
1.2.1. Health throughout the Life Course1.2.1. Health throughout the Life Course1.2.3. Non-Communicable and RareEU-Africa Global Health partner (EDCTP)3. Tackling diseases and reducing disease burden ()1.2.4. Infectious Diseases, including poverty-related and neglected diseasesRare Diseases4. Ensuring access to innovative, sustainable and high-quality health care ()1.2.6. Health Care SystemsOne Health AMR5. Unlocking the full potential of new tools, technologies and digital1.2.5. Tools, Technologies and Digital Solutions for Health and Care, includingPersonalised Medicine			
3. Tackling diseases and reducing disease burden ()Diseases(EDCTP)1.2.4. Infectious Diseases, including poverty-related and neglected diseasesRare Diseases4. Ensuring access to innovative, sustainable and high-quality health care ()1.2.6. Health Care SystemsTransformation of Health Care Sy EIT KIC Health5. Unlocking the full potential of new tools, technologies and digital1.2.5. Tools, Technologies and Digital Solutions for Health and Care, includingPersonalised Medicine		1.2.1. Health throughout the Life Course	
disease burden ()1.2.4. Infectious Diseases, including poverty-related and neglected diseasesRare Diseases4. Ensuring access to innovative, sustainable and high-quality health care ()1.2.6. Health Care SystemsTransformation of Health Care Sy EIT KIC Health5. Unlocking the full potential of new tools, technologies and digital1.2.5. Tools, Technologies and Digital Solutions for Health and Care, includingPersonalised Medicine			EU-Africa Global Health partnership (EDCTP)
4. Ensuring access to innovative, sustainable and high-quality health care ()       EIT KIC Health         5. Unlocking the full potential of new tools, technologies and digital       1.2.5. Tools, Technologies and Digital       Personalised Medicine			
tools, technologies and digital       Solutions for Health and Care, including	tainable and high-quality health	1.2.6. Health Care Systems	Transformation of Health Care Systems EIT KIC Health
solutions for a healthy society () personalised medicine	<b>·</b> ·		Personalised Medicine
6. Maintaining an innovative, sustainable and globally competitive health-related industry ()1.2.5. Tools, Technologies and Digital Health Innovation Partnet Solutions for Health and Care, including (Innovative Health Initiative- for personalised medicine1.2.6. Health Care Systems	tainable and globally competitive	Solutions for Health and Care, including personalised medicine	(Innovative Health Initiative- former



### **Impact Areas**

Expected Impact	Impact Areas
<ol> <li>Staying healthy in a rapidly changing society ()</li> </ol>	<ul> <li>healthier lifestyles &amp; behaviours, healthier environments, improved evidence-based health policies effective solutions</li> <li>better understanding of specific health &amp; care needs throughout the life course, incl. age-specific &amp; sex/gender-specific needs</li> <li>develop innovative services, guidelines and digital solution for people &amp; communities</li> <li>availability of real-world health data</li> </ul>
2. Living and working in a health-promoting environment ()	<ul> <li>Better understanding of environmental, occupational, social and economic determinants of health in living and working environments identify and assess the risks and benefits for health, to enable health promoting and disease preventive actions provide solid evidence</li> <li>stimulate uptake into environmental, occupational, social, economic, fiscal and health policies</li> <li>collaborations across sectors and with other clusters</li> </ul>
3. Tackling diseases and reducing disease burden ()	<ul> <li>infectious, poverty-related, neglected diseases, non-communicable &amp; rare diseases</li> <li>reduce the disease burden on patients</li> <li>better understanding of diseases</li> <li>improve existing prevention strategies to create tangible impacts</li> <li>better ability &amp; preparedness to manage epidemic outbreaks</li> <li>new prevention, public health interventions, diagnostics, vaccines, therapies, alternatives to antibiotics</li> </ul>

### **Impact Areas**

Expected Impact	Impact Areas Expected
4. Ensuring access to innovative, sustainable and high-quality health care ()	<ul> <li>equal access to innovative, sustainable and high-quality health care</li> <li>development and uptake of safe, cost-effective &amp; people-centred solutions</li> <li>focus on population health, health systems resilience, and evidence-based health policies</li> <li>innovative solutions in various dimensions (governance, financing, generation of human and physical resources, patient empowerment etc.)</li> </ul>
5. Unlocking the full potential of new tools, technologies and digital solutions for a healthy society ()	<ul> <li>New tools, health technologies &amp; digital solutions for biomedical research, prevention, diagnosis, therapy &amp; monitoring tailored to specific needs</li> <li>safety, effectiveness, inter-operability, accessibility, appropriateness, affordability, sustainability</li> <li>translate innovations into health policies &amp; practice</li> <li>multidisciplinary, cross-sector cooperation with key stakeholders (patients, care providers, researchers, regulatory bodies, policy-makers, funders)</li> <li>Al for analysis of health data advance care</li> </ul>
6. Maintaining an innovative, sustainable and globally competitive health-related industry ()	<ul> <li>Need for cross-sectorial research and innovation (integrating medical technologies, pharmaceuticals, biotechnologies, digital health and eHealth technologies)</li> <li>Supporting the standardisation policy, driving innovation from the demand side and providing evidence and guidelines for stakeholders and regulators to ensure take-up of innovations</li> <li>Support to studies for health assessment procedures, clinical performance demonstration, quality assurance schemes and standardisation</li> </ul>

**Intervention/Destination Area** Calls & Topics Call 1.1 – Staying healthy (2021) Topic 1.1 Prevention of **obesity** through the life course > Topic 1.2 Towards a molecular and neurological understanding of mental health and mental illness for the benefit of citizens and patients CSA 1.1 Supporting digital empowerment and health literacy Health throughout the Life 1. Call 1.2 – Staying healthy (2022) Course  $\geq$ Topic 1.3 Boosting mental health in Europe in times of change > Topic 1.4 The Silver Deal Topic 1.5 Personalised blue print of chronic inflammation in health-to-disease transition Topic 1.6 AI tools to predict the risk for chronic diseases CSA 1.2 Population cohorts for health research (international cooperation dimension) Call 2.1 – Environment and health (2021) Topic 2.1 Health risks related to exposure to **electromagnetic** fields (EMF) Topic 2.2 Indoor air quality and health  $\geq$ Topic 2.3 - Health impacts of climate change, costs and benefits of action and non-**Environmental and Social** 2. action **Health Determinants** Call 2.2 – Environment and health (2022) > Topic 2.4 Methods for assessing health-related costs of exposure to environmental stressors Topic 2.5 The role of **environmental pollution** in non-communicable diseases



Interventio	on Area	Calls
3. Non-Commu Rare Diseases	A A A A A A A A A A A A A A A A A A A	<ul> <li>II 3.1 – Tackling diseases (2021)         Topic 3.1 Comparative effectiveness research for healthcare interventions in areas of high public health need         Topic 3.2 Building a European innovation platform for the repurposing of medicinal products         Topic 3.12 Clinical development of health technologies relevant in sub-Saharan Africa         Topic 3.13 Advancing innovative Artificial Intelligence (AI)-based solutions for treatment         CSA 3.2 One Health AMR         CSA 3.3 EU Wide Clinical Trials Network - public health emergencies         II 3.2 – Tackling diseases (2022)         Topic 3.3 Towards improved palliation and/or end-of-life care         Topic 3.4 Pre-clinical development of the next generation immunotherapies         Topic 3.5 Vaccines 2.0 - using knowledge on host-pathogen interactions and novel technologies for the development of next generation of vaccines         Topic 3.6 Development of effective therapies for rare diseases with an unmet medical need         Output: Development of effective therapies for rare diseases with an unmet medical need         Output: Development of effective therapies for rare diseases with an unmet medical need         Output: Development of effective therapies for rare diseases         Topic 3.6 Development of effective therapies for rare diseases         Topic 3.6 Development of effective therapies for rare diseases         Topic 3.6 Development of effective therapies for rare diseases         Topic 3.6 Development of effective therapies for rare diseases         Topic 3.6 Development of effective therapies for rare diseases         Topic 3.6 Development of effective therapies for rare diseases         Topic 3.6 Development of effective therapies for rare diseases         Topic 3.6 Development of effective therapies for rare diseases         Topic 3.6 Development of effective therapi</li></ul>



### **Intervention Area** Call 4.1 – Ensuring access to innovative, sustainable and high-quality health care (2021) Topic 4.1 Improving quality of care and patient safety via quality assurance in health care Topic 4.2 Data-driven decision-support tools for better health and care delivery and policy-making

Topic 4.3 Personalised medicine and infectious diseases: understanding the individual host response to viruses (e.g., SARS-CoV-2)

Calls

- 4. Infectious Diseases. including poverty-related and neglected diseases
- Topic CSA 4.1 Health innovation procurers network
- Topic CSA 4.2 Identifying gaps to understand the full potential of personalised  $\geq$ prevention

### Call 4.2 – Ensuring access to innovative, sustainable and high-quality health care (2022)

- Topic 4.4 Pre-commercial procurement for environmentally sustainable and lowcarbon health and care systems
- Topic 4.5 Better economic foresight, financial planning and procurement/contractual strategies for health systems
- Topic 4.6 Innovation procurement instruments (PCP & PPI) for building the capacity of health and care systems in the context of recovery





### **Intervention Area**

personalised medicine

### Calls

Call 5.1 – Tools and technologies for a healthy society (2021)

- Topic 5.1 Smart medical devices and their surgical implantation for use in resourceconstrained settings
- Topic 5.2 Next generation advanced therapies to treat frequent and serious medical conditions with unmet needs
- Tools, Technologies and>Topic 5.9 Innovative tools for use and re-use of health data (in particular electronic<br/>health records and/or patient registries)and Care, including>

### Call 5.2 – Tools and technologies for a healthy society (2022)

- Topic 5.3. Optimising effectiveness in patients of existing prescription drugs, with the use of biomarkers, for major diseases (except cancer)
- Topic 5.4 New methods for the effective use of real-world data and/or synthetic data in regulatory decision-making and/or in health technology assessment
- > Topic 5.6 Computational models for new patient stratification strategies




5.





Intervention Area	Calls
6. Health Care Systems	<ul> <li>Call 6.1 – A competitive health-related industry (2021)</li> <li>Topic 6.1 Green pharmaceuticals</li> <li>Topic 6.2 New payment models for cost-effective and affordable health innovations/new models of pricing</li> <li>CSA 6.1 Uptake of Technical specifications for "Quality and Reliability of Health and Wellness Apps" – promoting a trusted 'mhealth label' in Europe</li> <li>Call 6.2 – A competitive health-related industry (2022)</li> <li>Topic 6.3 Enhancing Cybersecurity of connected Medical Devices</li> <li>Topic 6.4 Scaling up anonymization techniques, including secure multi-party computation for interoperable, trustable, cross-border health data hubs</li> <li>Topic 6.5 Development and procurement of new antimicrobials</li> <li>CSA 6.2 Setting up a 'European Smart Health Innovation Hub'</li> <li>CSA 6.3 Uptake of European Electronic Health Record Exchange Format</li> </ul>









International Cooperation

Will ensure effective tackling of global societal challenges; access to the world's best talents, expertise and resources; enhanced supply and demand of innovative solutions

20 Nov. 202

### Extended openness to association

Third countries with good capacity in science, technology and innovation Taking into account objective of driving economic growth in Europe through innovation

- General opening for international participation
- Intensified targeted actions (flagship initiatives, joint calls, etc.)





- Infectious diseases, antimicrobial resistances and public health emergencies.
- Global Health, through cooperation with the World Health Organisation (WHO)
- Personalised medicine, through dedicated actions and multilateral initiatives, such as the International Consortium for Personalised Medicine (ICPerMed)
- Chronic diseases, through dedicated actions and multilateral initiatives, such as the Global Alliance for Chronic Diseases (GACD) and the International Rare Diseases Research Consortium (IRDiRC).
- Cohorts-based clinical studies of health and diseases, through common approaches and protocols.
- Brain and Mental Health, through dedicated actions and multilateral initiatives, such as the International Initiative for Traumatic Brain Injury Research (InTBiR).
- Impact of the environment on human health, through dedicated research actions on the exposome and human biomonitoring, through e.g. cooperation with the WHO-Europe
- Improving access, sustainability and quality of health care in low- and middle-income countries (LMICs), in particular in Africa, through implementation research.

\* US participants of projects funded under the health cluster shall continue to be eligible for funding, in response to the openness of the USA NIH program to European researchers.













## Stay in contact with us!

SENET website:

→ Check Web-Series Calendar : <u>https://www.senet-hub.eu/</u>

SENET newsletter – subscribe to it! SENET Social media - follow us on Sand in Contact us: <u>SENETHub@steinbeis-europa.de</u>



